1 year ago



PhRMA: Who We Are,

PhRMA: Who We Are, Mission, and Annual Membership Survey companies. To accomplish this mission, PhRMA is dedicated to achieving these goals in Washington, DC, the states, and the world: • Broad patient access to safe and effective medicines through a free market, without price controls • Strong intellectual property incentives WHO WE ARE The Pharmaceutical Research and Manufacturers of America (PhRMA) represents the country’s leading biopharmaceutical companies, which are committed to discovering and developing medicines that save and improve lives. The work of the biopharmaceutical research sector brings hope to millions of patients, allowing them to live longer, healthier lives, while helping to manage health care costs. PhRMA member companies have invested nearly $700 billion in research and development into medical innovations since 2000, and an estimated $58.8 billion in 2015 alone. This investment also helps drive the industry’s significant contributions to the US economy, including the generation of hundreds of thousands of American jobs and vital support for local communities. OUR MISSION PhRMA’s mission is to conduct effective advocacy for public policies that encourage discovery of important new medicines for patients by pharmaceutical and biotechnology research • Transparent, efficient regulation and a free flow of information to patients PHRMA ANNUAL MEMBERSHIP SURVEY Please visit for the following annual survey results: R&D, PhRMA Member Companies Table 1: Domestic R&D and R&D Abroad, PhRMA Member Companies: 1980–2015 Table 2: R&D as a Percentage of Sales, PhRMA Member Companies: 1980–2015 Table 3: Domestic R&D and R&D Abroad, Human and Veterinary Use: 2014 Table 4: R&D by Function: 2014 Table 5: R&D by Geographic Area: 2014 Sales, PhRMA Member Companies Table 6: Domestic Sales and Sales Abroad: 1980–2015 Table 7: Sales by Geographic Area: 2014 72 Appendix

PhRMA Leadership 2016-2017 PRESIDENT & CEO Stephen J. Ubl PhRMA CHAIRMAN OF THE BOARD George A. Scangos, PhD Chief Executive Officer Biogen CHAIRMAN-ELECT Joaquin Duato Worldwide Chairman Pharmaceuticals Group Johnson & Johnson TREASURER Joseph Jimenez Chief Executive Officer Novartis AG BOARD MEMBERSHIP Carlos Alban Executive Vice President, Commercial Operations AbbVie Olivier Brandicourt, MD Chief Executive Officer Sanofi Paul R. Fonteyne President and Chief Executive Officer Boehringer Ingelheim USA Corporation Glenn J. Gormley, MD, PhD Chairman of the Board and President Daiichi Sankyo, Inc. Werner Baumann Chairman of the Board of Management Bayer AG Giovanni Caforio, MD Chief Executive Officer Bristol-Myers Squibb Company Kenneth C. Frazier Chairman, President and Chief Executive Officer Merck and Co., Inc. Peter Greenleaf Chief Executive Officer Sucampo Pharmaceuticals, Inc. Robert A. Bradway Chairman and Chief Executive Officer Amgen William H. Carson, MD President and Chief Executive Officer Otsuka Pharmaceutical Development and Commercialization, Inc. Belén Garijo, MD Member of the Executive Board and Chief Executive Officer Merck Healthcare EMD Serono Jesper Høiland Executive Vice President Novo Nordisk USA Appendix 73

Making a Killing AMENDED - Animal Aid
you can read it here. - Ratbags
I've Got Nothing to Lose by Trying It - Sense About Science
European Pharmaceutical Regulatory Law BOOT CAMP - Bristows
Life Science Newsletter No. 3 2010 - Plesner
Best Practice Model - Association of the British Pharmaceutical ...
I've Got Nothing to Lose by Trying It - Sense About Science